We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ONC Oncimmune Holdings Plc

0.00 (0.00%)
Last Updated: 08:00:17
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Oncimmune Holdings Plc ONC London Ordinary Share
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 23.50 08:00:17
Open Price Low Price High Price Close Price Previous Close
more quote information »
Industry Sector

Oncimmune ONC Dividends History

No dividends issued between 27 Feb 2014 and 27 Feb 2024

Top Dividend Posts

Top Posts
Posted at 12/10/2023 07:19 by brummy_git
Encouraging new developments from IPR rich life science firm Oncimmune.

All the details here.
Posted at 31/5/2023 10:15 by eva_1989
I dont know what Trek from LSE smoking but i badly need same ;)

He thought to pump before open so that he can sell to others...

Hi R00st3R,

I think todays interims answer your questions. All good at ONC. Well actually very good!

Should be a cracking day today!

Pity some of the revs got delayed but there is a line of sight and perhaps most importantly a change in sentiment.

Wish I could buy more at this price!

Usual caveats

Posted at 31/5/2023 08:33 by brummy_git
H1'23 results out today from Oncimmune. All the details here.
Posted at 22/5/2023 08:26 by brummy_git
Very positive M&A and contract news from global immunodiagnostics group Oncimmune today.

All the details here.
Posted at 27/2/2023 07:13 by brummy_git
Final results (y/e Aug'22) out today from global immunodiagnostics firm, Oncimmune

All the details here.
Posted at 17/2/2023 08:56 by brummy_git
Terrific news today from Oncimmune, who is partnering with with Siemens Healthineers to improve the assessment of indeterminate pulmonary nodules.

All the details here.
Posted at 20/12/2022 07:22 by brummy_git
More encouraging contract wins for leading immunodiagnostics firm, Oncimmune.

All the news and investor commentary here.
Posted at 14/12/2022 15:33 by brummy_git
Leading immunodiagnostics firm Oncimmune successfully competes a £2.1m top up fund raise. All the details & commentary here.
Posted at 26/11/2022 07:18 by brummy_git
There are 2 golden rules when investing in nascent healthcare stocks.

Find out here what they are & potentially how to profit from these secular tailwinds.
Posted at 05/5/2021 06:56 by someuwin
Zeus Capital


ONC LN Biotechnology

Reacquisition of IP and distribution rights for Chinese lung cancer test

Oncimmune has reacquired IP and distribution rights for its lung cancer diagnostic (EarlyCDT®) that has been recalibrated for enhanced accuracy in Asian populations. Trials are due to complete in H1 2021, with regulatory filing to follow shortly afterwards. We would expect the company to be in advanced discussions with a new licensee/ distributor or acquirer of the geographically-specific test, and that a new licensing agreement or divestment will be net value accretive. We maintain our positive outlook for Oncimmune, based on expectations of strong revenue growth and profitability. Valuation and current forecasts are under review pending an update by a new analyst.

Oncimmune has announced that it is reacquiring the IP and distribution rights for its EarlyCDT┬« lung cancer diagnostic in the Peoples Republic of China and Hong Kong, originally licensed to the Genostics Company Limited in January 2018. As part of the original deal Genostics made a £10m equity investment in Oncimmune. Genostics currently holds than less than a 5% share in Oncimmune. The cost of reacquisition has not been disclosed, and as such are likely to be relatively nonmaterial (i.e. < £1m).

Since January 2018 Oncimmune and Genostics have been developing a lung cancer test with superior performance given the high prevalence rates of EGFR +ve non-small cell lung cancer in the China and Asia-Pacific regions. The test uses an extended panel of autoantibodies to accommodate variations in the biomarkers expressed on cancer cells that are specific to Asian populations.

In May 2019 Oncimmune announced that the new test had entered a new multicentre case control study, in the People’s Republic of China assessing early detection of lung cancer, study approximately 1,000 early lung cancers at five leading academic health centres across China. The study is due to complete in H1 2021, with the data for the newly validated panel used to support approval of the test by Chinese regulators (the China National Medical Products Administration).

Oncimmune has been actively pursuing a new licensing partner for EarlyCDT┬« in China, and we would be surprised if, given that regulatory filing is likely before midmid, the company was not in advanced discussions with either a new licensee, or even a potential acquirer. We would expect a new licensing agreement or divestment to be net value accretive. We note that a reduced dependency on China as part of overall corporate strategy may be beneficial given Oncimmune’s intention. Going forwards, to increase its focus on the US, both in terms of operations and capital markets. We maintain a positive outlook on the stock, although our valuation and current forecasts are currently under review pending an update by a new analyst."

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |